These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 10855462)
41. Weight gain and antipsychotic medications. Aquila R; Emanuel M J Clin Psychiatry; 1999 May; 60(5):336-7. PubMed ID: 10362443 [No Abstract] [Full Text] [Related]
42. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Canuso CM; Goldstein JM; Wojcik J; Dawson R; Brandman D; Klibanski A; Schildkraut JJ; Green AI Psychiatry Res; 2002 Aug; 111(1):11-20. PubMed ID: 12140115 [TBL] [Abstract][Full Text] [Related]
43. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. Guille C; Sachs GS; Ghaemi SN J Clin Psychiatry; 2000 Sep; 61(9):638-42. PubMed ID: 11030483 [TBL] [Abstract][Full Text] [Related]
44. LORETA functional imaging in antipsychotic-naive and olanzapine-, clozapine- and risperidone-treated patients with schizophrenia. Tislerova B; Brunovsky M; Horacek J; Novak T; Kopecek M; Mohr P; Krajca V Neuropsychobiology; 2008; 58(1):1-10. PubMed ID: 18781085 [TBL] [Abstract][Full Text] [Related]
45. A retrospective study of clozapine and electroencephalographic abnormalities in schizophrenic patients. Chung SJ; Jeong SH; Ahn YM; Kang UG; Koo YJ; Ha JH; Lee SG; Kim YS Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan; 26(1):139-44. PubMed ID: 11853104 [TBL] [Abstract][Full Text] [Related]
46. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Citrome L; Volavka J; Czobor P; Sheitman B; Lindenmayer JP; McEvoy J; Cooper TB; Chakos M; Lieberman JA Psychiatr Serv; 2001 Nov; 52(11):1510-4. PubMed ID: 11684748 [TBL] [Abstract][Full Text] [Related]
47. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Revicki DA Schizophr Res; 1999 Mar; 35 Suppl():S101-9. PubMed ID: 10190231 [TBL] [Abstract][Full Text] [Related]
49. Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo. Baker RW; Ames D; Umbricht DS; Chengappa KN; Schooler NR Psychopharmacol Bull; 1996; 32(1):89-93. PubMed ID: 8927681 [TBL] [Abstract][Full Text] [Related]
50. Service use and costs of treating schizophrenia with atypical antipsychotics. Lewis M; McCrone P; Frangou S J Clin Psychiatry; 2001 Oct; 62(10):749-56. PubMed ID: 11816863 [TBL] [Abstract][Full Text] [Related]
51. Olanzapine appears haematologically safe in patients who developed blood dyscrasia on clozapine and risperidone. Dernovsek MZ; Tavcar R Int Clin Psychopharmacol; 2000 Jul; 15(4):237-8. PubMed ID: 10954065 [TBL] [Abstract][Full Text] [Related]
52. In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study. Dresel S; Mager T; Rossmüller B; Meisenzahl E; Hahn K; Möller HJ; Tatsch K Eur J Nucl Med; 1999 Aug; 26(8):862-8. PubMed ID: 10436199 [TBL] [Abstract][Full Text] [Related]
54. Comparative effectiveness of antipsychotic drugs. Messori A Am J Psychiatry; 2003 Mar; 160(3):591-2; author reply 592-3. PubMed ID: 12611854 [No Abstract] [Full Text] [Related]
55. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Fulton B; Goa KL Drugs; 1997 Feb; 53(2):281-98. PubMed ID: 9028746 [TBL] [Abstract][Full Text] [Related]
56. Novel antipsychotics: comparison of weight gain liabilities. Wirshing DA; Wirshing WC; Kysar L; Berisford MA; Goldstein D; Pashdag J; Mintz J; Marder SR J Clin Psychiatry; 1999 Jun; 60(6):358-63. PubMed ID: 10401912 [TBL] [Abstract][Full Text] [Related]
57. Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret? Stahl SM J Clin Psychiatry; 1999 Jul; 60(7):425-6. PubMed ID: 10453794 [TBL] [Abstract][Full Text] [Related]
58. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603 [TBL] [Abstract][Full Text] [Related]